Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin vaccine - DynPort

Drug Profile

Botulinum toxin vaccine - DynPort

Alternative Names: Botulism vaccine - DynPort; rBV A/B; recombinant botulinum neurotoxin vaccine; Recombinant botulinum vaccine A/B

Latest Information Update: 18 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Bacterial vaccines
  • Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Botulism

Most Recent Events

  • 04 Dec 2018 DynPort withdraws a phase III trial in healthy volunteers in Botulism (Prevention) in USA, prior to enrolment (IM) (NCT01940315)
  • 24 Oct 2018 DynPort plans to re-initiate a phase III trial in healthy volunteers in Botulism (Prevention) in USA (IM) (NCT01940315)
  • 09 Oct 2018 Botulinum toxin vaccine is still in phase II trials for Botulism (Prevention) in the US (NCT03676634)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top